| P50 | author | Seock-Ah Im | Q58821370 |
| | Do-Youn Oh | Q87569618 |
| | Tae-You Kim | Q87569625 |
| | Sae-Won Han | Q91404079 |
| | Jung-Hwan Yoon | Q39903625 |
| P2093 | author name string | Yoon Jun Kim | |
| | Kyung-Hun Lee | |
| | Tae-Yong Kim | |
| | Jeong-Hoon Lee | |
| | Su Jong Yu | |
| | Eun Ju Cho | |
| | Myoung-Jin Jang | |
| | Dae-Won Lee | |
| P2860 | cites work | Global cancer statistics, 2012 | Q27860501 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Hepatocellular carcinoma in cirrhosis: incidence and risk factors | Q28290048 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials | Q31014850 |
| | Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 |
| | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 |
| | Epidemiology of primary liver cancer | Q33750533 |
| | Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting | Q34131801 |
| | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 |
| | Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 |
| | Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses | Q35168766 |
| | Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? | Q36552819 |
| | SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 |
| | Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. | Q54542682 |
| | Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis | Q59901778 |
| | Early detection of liver cancer: diagnosis and management | Q37140022 |
| | Design and endpoints of clinical trials in hepatocellular carcinoma. | Q37162908 |
| | Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials | Q37614183 |
| | Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor | Q38283510 |
| | A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial | Q41201235 |
| | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| | Progression-free survival is a surrogate for survival in advanced colorectal cancer | Q46892021 |
| | The validation of surrogate endpoints in meta-analyses of randomized experiments | Q47671365 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International | Q42553662 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 1201-1205 | |
| P577 | publication date | 2016-10-13 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials | |
| P478 | volume | 115 | |